{"gene":"PRDM13","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":2013,"finding":"PRDM13 is a direct transcriptional target of PTF1A in the dorsal spinal cord; PTF1A activates PRDM13 expression, and PRDM13 in turn represses excitatory cell fate by binding to regulatory sequences near Tlx1 and Tlx3 genes to silence their expression.","method":"ChIP, reporter assays, gain/loss-of-function in mouse and Xenopus, epistasis","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (direct target validation, binding to regulatory sequences, genetic epistasis), replicated in two organisms","pmids":["23639443"],"is_preprint":false},{"year":2013,"finding":"PRDM13 interacts physically with the bHLH factor ASCL1 to repress ASCL1-mediated activation of Tlx3 in dorsal spinal cord inhibitory lineage specification.","method":"Co-immunoprecipitation, reporter assays, genetic epistasis in mouse","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 — reciprocal interaction demonstrated with functional consequence in vivo","pmids":["23639443"],"is_preprint":false},{"year":2013,"finding":"In Xenopus, PRDM13 is a histone methyltransferase-encoding gene downstream of PTF1A-Rbpj complex; Prdm13 knockdown upregulates Tlx3 (glutamatergic marker) and reduces Pax2 (GABAergic marker), and Prdm13 blocks Neurog2-mediated activation of Tlx3, establishing its role in balancing GABAergic vs. glutamatergic fate in the dorsal neural tube.","method":"Xenopus gain/loss-of-function (morpholino knockdown, overexpression), chick neural tube electroporation, RT-qPCR, in situ hybridization","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, multiple organisms, replicated in frog, mouse, and chick","pmids":["24370451"],"is_preprint":false},{"year":2013,"finding":"PRDM13 is subject to autonegative (autoinhibitory) regulation: knockdown leads to upregulation of Prdm13 transcription itself, suggesting a negative feedback loop on its own expression.","method":"Xenopus morpholino knockdown with RT-qPCR readout of Prdm13 transcript levels","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 3 — single organism, single method, but functionally linked","pmids":["24370451"],"is_preprint":false},{"year":2015,"finding":"PRDM13 is specifically expressed in developing and mature amacrine cells in the mouse retina; loss of Prdm13 reduces GABAergic and glycinergic amacrine cells causing a specific defect in the S2/S3 border neurite bundle, while forced expression of Prdm13 preferentially induces GABAergic and glycinergic (but not cholinergic) amacrine cells.","method":"Prdm13 knockout mice, retroviral overexpression, immunohistochemistry, retinal layer analysis","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — KO with specific cellular phenotype plus gain-of-function, multiple cell-type markers","pmids":["25995483"],"is_preprint":false},{"year":2015,"finding":"PRDM13 acts downstream of PTF1A in the retina; PTF1A induces all amacrine subtypes (GABAergic, glycinergic, cholinergic) while PRDM13 specifically induces only the GABAergic and glycinergic subtypes, placing PRDM13 downstream of PTF1A in a subtype-specific manner.","method":"Comparative gain-of-function of Prdm13 vs. Ptf1a in mouse retina with subtype marker immunohistochemistry","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — direct comparison of epistatic relationship, multiple markers","pmids":["25995483"],"is_preprint":false},{"year":2015,"finding":"Noncoding variants upstream of PRDM13 (within a DNase I hypersensitivity site) and tandem duplications of the PRDM13 gene cause North Carolina macular dystrophy; RT-PCR of developing human retinal stem cell–derived cells showed marked developmental regulation of PRDM13 expression, implicating dysregulation of PRDM13 in macular development.","method":"Whole-genome sequencing, Sanger sequencing, RT-PCR in stem cell-derived retinal cells, co-segregation analysis","journal":"Ophthalmology","confidence":"Medium","confidence_rationale":"Tier 3 — genetic/expression evidence linking regulatory variants to PRDM13 dysregulation, no direct functional assay of variant mechanism","pmids":["26507665"],"is_preprint":false},{"year":2014,"finding":"PRDM13 is specifically expressed in the compact region of the dorsomedial hypothalamus (DMH), where its expression is regulated by transcription factor NKX2-1; NKX2-1 upregulates the Prdm13 promoter, and NKX2-1 knockdown suppresses Prdm13 expression in primary hypothalamic neurons. DMH-specific Prdm13 knockdown causes reduced wake time and decreased sleep quality, as well as progressive adiposity.","method":"Laser-capture microdissection microarray, promoter reporter assay, siRNA knockdown in primary neurons, DMH-specific lentiviral knockdown in mice, EEG/EMG sleep analysis","journal":"Aging cell","confidence":"High","confidence_rationale":"Tier 2 — promoter regulation demonstrated in vitro, DMH-specific KD with defined behavioral/physiological phenotypes","pmids":["25546159"],"is_preprint":false},{"year":2017,"finding":"PRDM13 is recruited to chromatin by multiple neural bHLH factors (not just ASCL1) to repress gene expression programs for excitatory neuronal lineages; PRDM13 also ensures ventral neural tube specification genes (Olig1, Olig2, Prdm12) are excluded from dorsal regions, acting as a broad repressor of alternative fates in dorsal spinal cord neuronal lineage specification.","method":"ChIP-seq, RNA-seq in Prdm13 conditional KO mice, epistasis with bHLH factors","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1-2 — genome-wide ChIP-seq plus KO transcriptomics, multiple bHLH factor interactions tested","pmids":["28850031"],"is_preprint":false},{"year":2017,"finding":"In the mouse retina, Prdm13 is expressed in Ptf1a+ amacrine and horizontal precursors and is required for formation of Ebf3+ amacrine cell subtypes; loss of Prdm13 results in a 25% reduction of adult amacrine cells, loss of Ebf3+ amacrines, altered calretinin expression, and increased apoptosis—suggesting Prdm13 restricts competing fate programs to maintain amacrine subtype identity and survival.","method":"Prdm13 loss-of-function mouse (genetic KO), fate mapping, immunohistochemistry, TUNEL apoptosis assay, retinal progenitor overexpression","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 — clean KO with specific cellular phenotype, multiple markers, gain-of-function comparison","pmids":["29258872"],"is_preprint":false},{"year":2017,"finding":"In the Xenopus retina, Prdm13 is expressed predominantly in glycinergic amacrine cells; prdm13 overexpression favors amacrine fate with a bias toward glycinergic cells, while knockdown specifically inhibits glycinergic amacrine cell genesis. Prdm13 represses ptf1a expression, forming a negative feedback loop.","method":"Xenopus gain/loss-of-function (morpholino knockdown, overexpression), clonal analysis, RT-qPCR, in situ hybridization, immunohistochemistry","journal":"Neural development","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, clonal analysis, functional feedback loop demonstrated","pmids":["28863786"],"is_preprint":false},{"year":2021,"finding":"Recessive PRDM13 mutation in humans causes congenital hypogonadotropic hypogonadism and cerebellar hypoplasia; in Prdm13 mutant mice, there is a significant reduction in hypothalamic Kisspeptin (Kiss1) neurons and PAX2+ cerebellar progenitors, with ectopic expression of glutamatergic marker TLX3, establishing PRDM13 as a regulator of GABAergic fate in the cerebellum and of Kiss1 neuron development in the hypothalamus.","method":"Human genetic analysis, mouse Prdm13 mutant allele analysis, immunohistochemistry for Kiss1/PAX2/TLX3, expression studies in mouse and human tissue","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — mutant mouse phenotype with specific cellular markers corroborated by human genetic evidence","pmids":["34730112"],"is_preprint":false},{"year":2022,"finding":"Biallelic loss-of-function mutations in PRDM13 in humans cause pontocerebellar hypoplasia with dysplasia of the dentate nucleus, inferior olive hypoplasia, and disorganized Purkinje cell layer. In zebrafish, prdm13 loss causes reduction in Purkinje cell numbers and complete absence of inferior olive nuclei. snRNA-seq and ISH show PRDM13 expression in cerebellar ventricular zone GABAergic progenitors (including Purkinje cell precursors).","method":"Human genetic analysis (biallelic variants), zebrafish prdm13 loss-of-function, snRNA-seq data mining, in situ hybridization, histopathology","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 — zebrafish KO with specific cellular phenotype, human pathology, complementary expression data","pmids":["35390279"],"is_preprint":false},{"year":2023,"finding":"Prdm13+ neurons in the dorsomedial hypothalamus are activated during sleep deprivation in young but not old mice; chemogenetic inhibition of DMH Prdm13+ neurons promotes increased sleep attempts during sleep deprivation; DMH-specific Prdm13 KO mice show age-associated sleep fragmentation, increased adiposity, decreased physical activity, and shortened lifespan, with dietary restriction effects on sleep abrogated in KO mice.","method":"Chemogenetic (DREADD) inhibition of Prdm13+ neurons, DMH-specific Prdm13 KO, c-Fos immunostaining, EEG/EMG sleep recording, metabolic phenotyping","journal":"Life science alliance","confidence":"High","confidence_rationale":"Tier 2 — chemogenetics + conditional KO with defined behavioral and physiological phenotypes","pmids":["37045472"],"is_preprint":false},{"year":2018,"finding":"Overexpression of PRDM13 in U87 glioma cells decreases proliferation, migration, and invasion; RNA-seq and functional follow-up identified upregulation of DLC1 (deleted in liver cancer 1), a Rho GTPase-activating protein, as a downstream effector of PRDM13-mediated growth suppression.","method":"Overexpression in U87 cells, RNA-seq, functional proliferation/migration/invasion assays, western blot validation","journal":"International journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, overexpression with functional assays and RNA-seq, limited mechanistic depth","pmids":["29767251"],"is_preprint":false},{"year":2025,"finding":"In mouse embryonic stem cell–derived neuroectoderm organoids, Prdm13 expression inhibits RX+ eye field fate while permitting non-eye field neuroectoderm differentiation; this effect depends on the first and second zinc-finger domains of PRDM13. Mechanistically, Prdm13 activates WNT/β-catenin signaling, downregulating eye field transcription factors; pharmacological WNT inhibition abolishes PRDM13-mediated suppression of eye field fate.","method":"mESC-derived organoids, Prdm13 overexpression, domain deletion mutants (zinc-finger 1 and 2), WNT pathway reporter assays, pharmacological WNT inhibition, immunofluorescence","journal":"Stem cell reports","confidence":"High","confidence_rationale":"Tier 1-2 — domain mutagenesis, pharmacological rescue, organoid system with multiple orthogonal readouts","pmids":["40409260"],"is_preprint":false},{"year":2025,"finding":"Elevated PRDM13 in the mouse retina decreases photoreceptor function and survival; transcriptomic profiling revealed that elevated PRDM13 downregulates Prdm1 (a photoreceptor marker) and Nr2e3 (a key photoreceptor specification regulator), as well as NR2E3's direct and indirect targets, and deregulates genes involved in phototransduction and retinal development.","method":"Inducible mouse PRDM13 overexpression model, ERG, histology, RNA-seq, qPCR, western blot","journal":"Investigative ophthalmology & visual science","confidence":"High","confidence_rationale":"Tier 2 — inducible mouse model with reversal experiment, transcriptomic profiling, and multiple validation methods","pmids":["40824246"],"is_preprint":false},{"year":2025,"finding":"In the mouse cerebellum, PRDM13 loss (multiple mutant alleles) causes loss of PAX2+ inhibitory interneurons and Purkinje cells, increased TLX3+ excitatory neurons, increased apoptosis, misplacement of TBR1+ cells, and reduced cerebellar size—phenocopying PTF1A absence and establishing PRDM13 as required downstream of PTF1A for balanced inhibitory/excitatory neuronal specification in the cerebellum.","method":"Multiple Prdm13 mutant mouse alleles, immunohistochemistry for PAX2/TLX3/TBR1/Purkinje cell markers, epistasis with Ptf1a","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 — multiple alleles phenocopying PTF1A KO, multiple marker readouts, epistatic relationship clearly established","pmids":["40721003"],"is_preprint":false},{"year":2024,"finding":"PRDM13 binds DNA in a methylation-sensitive manner, with binding to methylated DNA preferred or resulting in discovery of alternative, methylation-dependent binding motifs, as determined by meSMiLE-seq.","method":"meSMiLE-seq (microfluidic in vitro DNA binding assay with methylated and unmethylated DNA)","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1 — in vitro biochemical assay, but preprint and single method without cellular validation","pmids":["bio_10.1101_2024.11.11.619598"],"is_preprint":true}],"current_model":"PRDM13 is a transcriptional repressor that acts downstream of the PTF1A-RBPJ complex to suppress glutamatergic/excitatory neuronal fate programs (including TLX1/3 and ventral specification genes) while promoting GABAergic/inhibitory neuronal identity in the dorsal spinal cord, cerebellum, retina, and hypothalamus; it achieves repression by binding regulatory sequences near target genes and interacting with bHLH factors (ASCL1, NEUROG2, and others), requires its zinc-finger domains for DNA binding (including methylation-sensitive binding), activates WNT/β-catenin signaling to suppress eye field fate in retinal progenitors, and when dysregulated (by noncoding variants or gene duplication) causes North Carolina macular dystrophy and related retinal dystrophies, while recessive loss-of-function mutations cause pontocerebellar hypoplasia and congenital hypogonadotropic hypogonadism."},"narrative":{"teleology":[{"year":2013,"claim":"Establishing PRDM13 as the critical downstream effector of PTF1A in dorsal spinal cord that directly represses excitatory fate: prior work identified PTF1A as a master regulator of inhibitory neuron specification, but the mechanism by which it silenced glutamatergic genes was unknown—PRDM13 was shown to directly bind Tlx1/Tlx3 regulatory elements and repress their transcription, while physically interacting with bHLH factor ASCL1 to block ASCL1-mediated Tlx3 activation.","evidence":"ChIP, reporter assays, co-immunoprecipitation, gain/loss-of-function epistasis in mouse and Xenopus","pmids":["23639443","24370451"],"confidence":"High","gaps":["Whether PRDM13 possesses intrinsic histone methyltransferase activity was not directly demonstrated","The identity of additional bHLH partners beyond ASCL1 remained unresolved","No genome-wide binding profile was available"]},{"year":2015,"claim":"Extending the PTF1A→PRDM13 axis to retinal neuron subtype specification: it was unclear whether PRDM13 had tissue-specific roles beyond spinal cord—knockout and overexpression studies showed PRDM13 specifically promotes GABAergic and glycinergic (but not cholinergic) amacrine cell identity in the retina, acting as a subtype-selective effector downstream of PTF1A.","evidence":"Prdm13 KO mice, retroviral overexpression, subtype marker immunohistochemistry in mouse retina","pmids":["25995483"],"confidence":"High","gaps":["Direct transcriptional targets of PRDM13 in retina were not identified","How PRDM13 distinguishes GABAergic/glycinergic from cholinergic amacrine programs was unexplained"]},{"year":2015,"claim":"Linking PRDM13 regulatory variants to human macular disease: it was unknown which gene was responsible for North Carolina macular dystrophy—noncoding variants upstream of PRDM13 and PRDM13 tandem duplications were identified as causal, establishing that PRDM13 dosage dysregulation disrupts macular development.","evidence":"Whole-genome sequencing, co-segregation analysis, RT-PCR in human retinal stem cell-derived cells","pmids":["26507665"],"confidence":"Medium","gaps":["No direct functional assay demonstrated how the noncoding variants alter PRDM13 expression levels","Whether gain versus loss of PRDM13 expression drives macular pathology was not resolved"]},{"year":2014,"claim":"Revealing a hypothalamic role for PRDM13 in sleep and metabolic regulation: PRDM13 function had only been studied in neuronal fate specification—discovery of NKX2-1-regulated PRDM13 expression in the dorsomedial hypothalamus and the sleep/adiposity phenotypes upon DMH-specific knockdown established a novel physiological role.","evidence":"Laser-capture microarray, promoter reporter, siRNA in primary neurons, DMH-specific lentiviral KD in mice with EEG/EMG and metabolic phenotyping","pmids":["25546159"],"confidence":"High","gaps":["The downstream transcriptional targets of PRDM13 in DMH neurons were not identified","Whether PRDM13 acts through the same bHLH-dependent repressor mechanism in hypothalamus was untested"]},{"year":2017,"claim":"Defining PRDM13 as a genome-wide repressor of alternative neuronal fates recruited by multiple bHLH factors: it was unclear whether PRDM13 only interacted with ASCL1—ChIP-seq and conditional KO transcriptomics showed PRDM13 is recruited by multiple bHLH partners and represses ventral specification genes (Olig1, Olig2, Prdm12) in addition to excitatory markers, broadening its role as a gatekeeper of dorsal identity.","evidence":"ChIP-seq, RNA-seq in Prdm13 conditional KO mice, epistasis with multiple bHLH factors","pmids":["28850031"],"confidence":"High","gaps":["The biochemical nature of the repressive complex (co-repressors, histone marks deposited) was not characterized","Structural basis for bHLH factor recognition by PRDM13 was unknown"]},{"year":2017,"claim":"Refining retinal amacrine subtype roles of PRDM13 and establishing a PTF1A-PRDM13 negative feedback loop: in Xenopus retina, PRDM13 was shown to repress its own upstream activator Ptf1a, creating feedback regulation, while mouse KO confirmed loss of Ebf3+ amacrine subtypes and increased apoptosis.","evidence":"Xenopus clonal analysis and morpholino knockdown; mouse Prdm13 KO with fate mapping, TUNEL assay, immunohistochemistry","pmids":["28863786","29258872"],"confidence":"High","gaps":["Whether the negative feedback on Ptf1a is direct or indirect was not resolved","The apoptosis mechanism in amacrine cells lacking PRDM13 was not elucidated"]},{"year":2021,"claim":"Establishing PRDM13 as a Mendelian disease gene: recessive PRDM13 mutations in humans were linked to congenital hypogonadotropic hypogonadism and cerebellar hypoplasia, with mouse mutants revealing loss of hypothalamic Kiss1 neurons and cerebellar PAX2+ progenitors with ectopic TLX3 expression—directly connecting the excitatory/inhibitory fate switch to human disease.","evidence":"Human genetic analysis, Prdm13 mutant mouse immunohistochemistry for Kiss1/PAX2/TLX3","pmids":["34730112"],"confidence":"High","gaps":["The mechanism by which PRDM13 regulates Kiss1 neuron development was not determined","Whether PRDM13 acts cell-autonomously in Kiss1 precursors was not shown"]},{"year":2022,"claim":"Defining the cerebellar neuropathology of PRDM13 deficiency: biallelic human mutations were shown to cause pontocerebellar hypoplasia with dentate nucleus dysplasia and inferior olive hypoplasia, confirmed by zebrafish prdm13 loss causing Purkinje cell reduction and absent inferior olive, with snRNA-seq localizing PRDM13 to GABAergic ventricular zone progenitors.","evidence":"Human neuropathology, zebrafish prdm13 KO, snRNA-seq, in situ hybridization","pmids":["35390279"],"confidence":"High","gaps":["The direct transcriptional targets of PRDM13 in the cerebellum were not mapped","Whether pontine defects are secondary to cerebellar or olivary loss was not established"]},{"year":2023,"claim":"Demonstrating that PRDM13+ DMH neurons are active participants in sleep homeostasis that decline with aging: chemogenetic silencing of these neurons promoted sleep attempts, and DMH-specific Prdm13 KO recapitulated age-related sleep fragmentation and metabolic dysfunction, establishing PRDM13 as functionally required in adult hypothalamic circuits.","evidence":"DREADD chemogenetic inhibition, DMH-specific Prdm13 conditional KO, c-Fos, EEG/EMG, metabolic phenotyping","pmids":["37045472"],"confidence":"High","gaps":["The molecular targets of PRDM13 in adult DMH neurons are unknown","Whether PRDM13 loss causes neuron loss versus altered function in adult DMH was not distinguished"]},{"year":2025,"claim":"Revealing that PRDM13 suppresses eye field fate through WNT/β-catenin activation dependent on its zinc-finger domains, and that elevated retinal PRDM13 is directly toxic to photoreceptors by downregulating Prdm1 and Nr2e3—providing a mechanistic link between PRDM13 dosage and retinal dystrophy.","evidence":"mESC-derived organoids with domain deletion mutants and WNT pathway pharmacological rescue; inducible PRDM13 overexpression mouse with ERG, histology, and RNA-seq","pmids":["40409260","40824246"],"confidence":"High","gaps":["Whether WNT activation is a direct or indirect consequence of PRDM13 zinc-finger binding was not determined","The binding sites through which PRDM13 represses Prdm1 and Nr2e3 were not mapped","Whether the photoreceptor toxicity explains human NCMD pathology was not directly tested"]},{"year":2025,"claim":"Confirming PRDM13 as essential downstream of PTF1A for balanced inhibitory/excitatory specification in the cerebellum: multiple Prdm13 mutant alleles phenocopied Ptf1a loss with loss of PAX2+ interneurons and Purkinje cells, gain of TLX3+ excitatory neurons, and reduced cerebellar size.","evidence":"Multiple Prdm13 mutant mouse alleles, immunohistochemistry for PAX2/TLX3/TBR1/Purkinje cell markers, epistasis with Ptf1a","pmids":["40721003"],"confidence":"High","gaps":["Whether PRDM13 acts in the same progenitor pool as PTF1A or also in postmitotic cells was not resolved","The identity of PRDM13-associated co-repressor complexes in cerebellar progenitors remains unknown"]},{"year":null,"claim":"Key open questions include the biochemical nature of PRDM13's repressive activity (whether it has intrinsic histone methyltransferase activity, its co-repressor partners, and structural basis for bHLH interaction), the direct genomic targets in hypothalamic and cerebellar tissues, and the precise mechanism by which PRDM13 dosage dysregulation causes North Carolina macular dystrophy.","evidence":"","pmids":[],"confidence":"Low","gaps":["No reconstituted enzymatic assay has confirmed or excluded intrinsic histone methyltransferase activity","Co-repressor complex composition is entirely uncharacterized","Genome-wide binding data exist only for dorsal spinal cord, not retina, cerebellum, or hypothalamus"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,2,8,10,15,16]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,8,18]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,8,15]}],"pathway":[{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,2,4,5,9,11,12,17]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,8,15,16]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[4,9,11,12,13,17]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[15]}],"complexes":[],"partners":["ASCL1","NEUROG2","PTF1A","NKX2-1","DLC1"],"other_free_text":[]},"mechanistic_narrative":"PRDM13 is a transcriptional repressor that functions downstream of PTF1A to suppress excitatory/glutamatergic neuronal fate and promote inhibitory (GABAergic/glycinergic) neuronal identity across multiple regions of the developing nervous system, including the dorsal spinal cord, cerebellum, retina, and hypothalamus. It is recruited to chromatin by neural bHLH transcription factors such as ASCL1 and NEUROG2, where it binds regulatory sequences near target genes (e.g., Tlx1, Tlx3, Olig1/2) to silence excitatory and alternative lineage programs; its zinc-finger domains are required for DNA binding and for suppression of eye field fate through activation of WNT/β-catenin signaling in retinal progenitors [PMID:23639443, PMID:28850031, PMID:40409260]. Biallelic loss-of-function mutations in PRDM13 cause pontocerebellar hypoplasia and congenital hypogonadotropic hypogonadism in humans, while noncoding regulatory variants and gene duplications cause North Carolina macular dystrophy [PMID:35390279, PMID:34730112, PMID:26507665]. In the hypothalamus, PRDM13 marks dorsomedial hypothalamic neurons that regulate sleep homeostasis, and its loss leads to sleep fragmentation, progressive adiposity, and shortened lifespan [PMID:37045472, PMID:25546159]."},"prefetch_data":{"uniprot":{"accession":"Q9H4Q3","full_name":"PR domain zinc finger protein 13","aliases":["PR domain-containing protein 13"],"length_aa":707,"mass_kda":74.0,"function":"May be involved in transcriptional regulation. Is required for the differentiation of KISS1-expressing neurons in the arcuate (Arc) nucleus of the hypothalamus. Is a critical regulator of GABAergic cell fate in the cerebellum, required for normal postnatal cerebellar development (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9H4Q3/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PRDM13","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PRDM13","total_profiled":1310},"omim":[{"mim_id":"619909","title":"PONTOCEREBELLAR HYPOPLASIA, TYPE 17; PCH17","url":"https://www.omim.org/entry/619909"},{"mim_id":"619761","title":"CEREBELLAR DYSFUNCTION, IMPAIRED INTELLECTUAL DEVELOPMENT, AND HYPOGONADOTROPIC HYPOGONADISM; CDIDHH","url":"https://www.omim.org/entry/619761"},{"mim_id":"616842","title":"DNase1 HYPERSENSITIVITY, CHROMOSOME 6, SITE 1; DHS6S1","url":"https://www.omim.org/entry/616842"},{"mim_id":"616741","title":"PR DOMAIN-CONTAINING PROTEIN 13; PRDM13","url":"https://www.omim.org/entry/616741"},{"mim_id":"608850","title":"MACULAR DYSTROPHY, RETINAL, 3; MCDR3","url":"https://www.omim.org/entry/608850"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Nuclear speckles","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Not detected","tissue_distribution":"Not detected","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PRDM13"},"hgnc":{"alias_symbol":["PFM10"],"prev_symbol":[]},"alphafold":{"accession":"Q9H4Q3","domains":[{"cath_id":"2.170.270.10","chopping":"12-122","consensus_level":"high","plddt":78.9268,"start":12,"end":122},{"cath_id":"3.30.160","chopping":"123-160","consensus_level":"medium","plddt":71.2111,"start":123,"end":160}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H4Q3","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H4Q3-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H4Q3-F1-predicted_aligned_error_v6.png","plddt_mean":52.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PRDM13","jax_strain_url":"https://www.jax.org/strain/search?query=PRDM13"},"sequence":{"accession":"Q9H4Q3","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H4Q3.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H4Q3/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H4Q3"}},"corpus_meta":[{"pmid":"26507665","id":"PMC_26507665","title":"North Carolina Macular Dystrophy Is Caused by Dysregulation of the Retinal Transcription Factor PRDM13.","date":"2015","source":"Ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/26507665","citation_count":92,"is_preprint":false},{"pmid":"23639443","id":"PMC_23639443","title":"Prdm13 mediates the balance of inhibitory and excitatory neurons in somatosensory circuits.","date":"2013","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/23639443","citation_count":58,"is_preprint":false},{"pmid":"25995483","id":"PMC_25995483","title":"Prdm13 regulates subtype specification of retinal amacrine interneurons and modulates visual sensitivity.","date":"2015","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25995483","citation_count":55,"is_preprint":false},{"pmid":"24370451","id":"PMC_24370451","title":"The Prdm13 histone methyltransferase encoding gene is a Ptf1a-Rbpj downstream target that suppresses glutamatergic and promotes GABAergic neuronal fate in the dorsal neural tube.","date":"2013","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/24370451","citation_count":40,"is_preprint":false},{"pmid":"28850031","id":"PMC_28850031","title":"Repression by PRDM13 is critical for generating precision in neuronal identity.","date":"2017","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/28850031","citation_count":35,"is_preprint":false},{"pmid":"27777503","id":"PMC_27777503","title":"North Carolina macular dystrophy (MCDR1) caused by a novel tandem duplication of the PRDM13 gene.","date":"2016","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/27777503","citation_count":30,"is_preprint":false},{"pmid":"25546159","id":"PMC_25546159","title":"Deficiency of Prdm13, a dorsomedial hypothalamus-enriched gene, mimics age-associated changes in sleep quality and adiposity.","date":"2014","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/25546159","citation_count":27,"is_preprint":false},{"pmid":"34730112","id":"PMC_34730112","title":"A recessive PRDM13 mutation results in congenital hypogonadotropic hypogonadism and cerebellar hypoplasia.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/34730112","citation_count":23,"is_preprint":false},{"pmid":"30710461","id":"PMC_30710461","title":"Unique noncoding variants upstream of PRDM13 are associated with a spectrum of developmental retinal dystrophies including progressive bifocal chorioretinal atrophy.","date":"2019","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/30710461","citation_count":21,"is_preprint":false},{"pmid":"29258872","id":"PMC_29258872","title":"Prdm13 is required for Ebf3+ amacrine cell formation in the retina.","date":"2017","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/29258872","citation_count":19,"is_preprint":false},{"pmid":"35390279","id":"PMC_35390279","title":"Recessive PRDM13 mutations cause fatal perinatal brainstem dysfunction with cerebellar hypoplasia and disrupt Purkinje cell differentiation.","date":"2022","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35390279","citation_count":18,"is_preprint":false},{"pmid":"28863786","id":"PMC_28863786","title":"Prdm13 forms a feedback loop with Ptf1a and is required for glycinergic amacrine cell genesis in the Xenopus Retina.","date":"2017","source":"Neural development","url":"https://pubmed.ncbi.nlm.nih.gov/28863786","citation_count":18,"is_preprint":false},{"pmid":"32476814","id":"PMC_32476814","title":"A unique PRDM13-associated variant in a Georgian Jewish family with probable North Carolina macular dystrophy and the possible contribution of a unique CFH variant.","date":"2020","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/32476814","citation_count":15,"is_preprint":false},{"pmid":"34526759","id":"PMC_34526759","title":"A novel duplication involving PRDM13 in a Turkish family supports its role in North Carolina macular dystrophy (NCMD/MCDR1).","date":"2021","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/34526759","citation_count":13,"is_preprint":false},{"pmid":"34427740","id":"PMC_34427740","title":"A novel tandem duplication of PRDM13 in a Chinese family with North Carolina macular dystrophy.","date":"2021","source":"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","url":"https://pubmed.ncbi.nlm.nih.gov/34427740","citation_count":10,"is_preprint":false},{"pmid":"37045472","id":"PMC_37045472","title":"Sleep-wake patterns are altered with age, Prdm13 signaling in the DMH, and diet restriction in mice.","date":"2023","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/37045472","citation_count":8,"is_preprint":false},{"pmid":"29767251","id":"PMC_29767251","title":"Overexpression of PRDM13 inhibits glioma cells via Rho and GTP enzyme activation protein.","date":"2018","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29767251","citation_count":7,"is_preprint":false},{"pmid":"33809237","id":"PMC_33809237","title":"Investigation of PRDM10 and PRDM13 Expression in Developing Mouse Embryos by an Optimized PACT-Based Embryo Clearing Method.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33809237","citation_count":4,"is_preprint":false},{"pmid":"36007168","id":"PMC_36007168","title":"CONGENITAL POSTERIOR POLAR CHORIORETINAL HYPOPLASIA: Expansion of the Clinical Spectrum, Mutation, and Its Association With PRDM13.","date":"2022","source":"Retina (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/36007168","citation_count":4,"is_preprint":false},{"pmid":"39959174","id":"PMC_39959174","title":"A novel PRDM13 gene duplication causing congenital North Carolina macular dystrophy phenotype in a Mexican family.","date":"2024","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/39959174","citation_count":2,"is_preprint":false},{"pmid":"40409260","id":"PMC_40409260","title":"A zinc finger-dependent, PRDM13-driven mechanism regulates retinal progenitor cell fate from mouse embryonic stem cells via WNT signaling.","date":"2025","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/40409260","citation_count":1,"is_preprint":false},{"pmid":"40824246","id":"PMC_40824246","title":"Elevated PRDM13 Disrupts Photoreceptor Function and Survival in the Mammalian Retina.","date":"2025","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/40824246","citation_count":0,"is_preprint":false},{"pmid":"40721003","id":"PMC_40721003","title":"PRDM13 is required for specification of PAX2 lineage inhibitory neurons in the developing cerebellum.","date":"2025","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/40721003","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.11.11.619598","title":"Identification of methylation-sensitive human transcription factors using meSMiLE-seq","date":"2024-11-12","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.11.619598","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":13896,"output_tokens":4741,"usd":0.056402},"stage2":{"model":"claude-opus-4-6","input_tokens":8231,"output_tokens":3691,"usd":0.200145},"total_usd":0.256547,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"PRDM13 is a direct transcriptional target of PTF1A in the dorsal spinal cord; PTF1A activates PRDM13 expression, and PRDM13 in turn represses excitatory cell fate by binding to regulatory sequences near Tlx1 and Tlx3 genes to silence their expression.\",\n      \"method\": \"ChIP, reporter assays, gain/loss-of-function in mouse and Xenopus, epistasis\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (direct target validation, binding to regulatory sequences, genetic epistasis), replicated in two organisms\",\n      \"pmids\": [\"23639443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PRDM13 interacts physically with the bHLH factor ASCL1 to repress ASCL1-mediated activation of Tlx3 in dorsal spinal cord inhibitory lineage specification.\",\n      \"method\": \"Co-immunoprecipitation, reporter assays, genetic epistasis in mouse\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal interaction demonstrated with functional consequence in vivo\",\n      \"pmids\": [\"23639443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In Xenopus, PRDM13 is a histone methyltransferase-encoding gene downstream of PTF1A-Rbpj complex; Prdm13 knockdown upregulates Tlx3 (glutamatergic marker) and reduces Pax2 (GABAergic marker), and Prdm13 blocks Neurog2-mediated activation of Tlx3, establishing its role in balancing GABAergic vs. glutamatergic fate in the dorsal neural tube.\",\n      \"method\": \"Xenopus gain/loss-of-function (morpholino knockdown, overexpression), chick neural tube electroporation, RT-qPCR, in situ hybridization\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, multiple organisms, replicated in frog, mouse, and chick\",\n      \"pmids\": [\"24370451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PRDM13 is subject to autonegative (autoinhibitory) regulation: knockdown leads to upregulation of Prdm13 transcription itself, suggesting a negative feedback loop on its own expression.\",\n      \"method\": \"Xenopus morpholino knockdown with RT-qPCR readout of Prdm13 transcript levels\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single organism, single method, but functionally linked\",\n      \"pmids\": [\"24370451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PRDM13 is specifically expressed in developing and mature amacrine cells in the mouse retina; loss of Prdm13 reduces GABAergic and glycinergic amacrine cells causing a specific defect in the S2/S3 border neurite bundle, while forced expression of Prdm13 preferentially induces GABAergic and glycinergic (but not cholinergic) amacrine cells.\",\n      \"method\": \"Prdm13 knockout mice, retroviral overexpression, immunohistochemistry, retinal layer analysis\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO with specific cellular phenotype plus gain-of-function, multiple cell-type markers\",\n      \"pmids\": [\"25995483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PRDM13 acts downstream of PTF1A in the retina; PTF1A induces all amacrine subtypes (GABAergic, glycinergic, cholinergic) while PRDM13 specifically induces only the GABAergic and glycinergic subtypes, placing PRDM13 downstream of PTF1A in a subtype-specific manner.\",\n      \"method\": \"Comparative gain-of-function of Prdm13 vs. Ptf1a in mouse retina with subtype marker immunohistochemistry\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct comparison of epistatic relationship, multiple markers\",\n      \"pmids\": [\"25995483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Noncoding variants upstream of PRDM13 (within a DNase I hypersensitivity site) and tandem duplications of the PRDM13 gene cause North Carolina macular dystrophy; RT-PCR of developing human retinal stem cell–derived cells showed marked developmental regulation of PRDM13 expression, implicating dysregulation of PRDM13 in macular development.\",\n      \"method\": \"Whole-genome sequencing, Sanger sequencing, RT-PCR in stem cell-derived retinal cells, co-segregation analysis\",\n      \"journal\": \"Ophthalmology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — genetic/expression evidence linking regulatory variants to PRDM13 dysregulation, no direct functional assay of variant mechanism\",\n      \"pmids\": [\"26507665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PRDM13 is specifically expressed in the compact region of the dorsomedial hypothalamus (DMH), where its expression is regulated by transcription factor NKX2-1; NKX2-1 upregulates the Prdm13 promoter, and NKX2-1 knockdown suppresses Prdm13 expression in primary hypothalamic neurons. DMH-specific Prdm13 knockdown causes reduced wake time and decreased sleep quality, as well as progressive adiposity.\",\n      \"method\": \"Laser-capture microdissection microarray, promoter reporter assay, siRNA knockdown in primary neurons, DMH-specific lentiviral knockdown in mice, EEG/EMG sleep analysis\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — promoter regulation demonstrated in vitro, DMH-specific KD with defined behavioral/physiological phenotypes\",\n      \"pmids\": [\"25546159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PRDM13 is recruited to chromatin by multiple neural bHLH factors (not just ASCL1) to repress gene expression programs for excitatory neuronal lineages; PRDM13 also ensures ventral neural tube specification genes (Olig1, Olig2, Prdm12) are excluded from dorsal regions, acting as a broad repressor of alternative fates in dorsal spinal cord neuronal lineage specification.\",\n      \"method\": \"ChIP-seq, RNA-seq in Prdm13 conditional KO mice, epistasis with bHLH factors\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genome-wide ChIP-seq plus KO transcriptomics, multiple bHLH factor interactions tested\",\n      \"pmids\": [\"28850031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In the mouse retina, Prdm13 is expressed in Ptf1a+ amacrine and horizontal precursors and is required for formation of Ebf3+ amacrine cell subtypes; loss of Prdm13 results in a 25% reduction of adult amacrine cells, loss of Ebf3+ amacrines, altered calretinin expression, and increased apoptosis—suggesting Prdm13 restricts competing fate programs to maintain amacrine subtype identity and survival.\",\n      \"method\": \"Prdm13 loss-of-function mouse (genetic KO), fate mapping, immunohistochemistry, TUNEL apoptosis assay, retinal progenitor overexpression\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with specific cellular phenotype, multiple markers, gain-of-function comparison\",\n      \"pmids\": [\"29258872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In the Xenopus retina, Prdm13 is expressed predominantly in glycinergic amacrine cells; prdm13 overexpression favors amacrine fate with a bias toward glycinergic cells, while knockdown specifically inhibits glycinergic amacrine cell genesis. Prdm13 represses ptf1a expression, forming a negative feedback loop.\",\n      \"method\": \"Xenopus gain/loss-of-function (morpholino knockdown, overexpression), clonal analysis, RT-qPCR, in situ hybridization, immunohistochemistry\",\n      \"journal\": \"Neural development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, clonal analysis, functional feedback loop demonstrated\",\n      \"pmids\": [\"28863786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Recessive PRDM13 mutation in humans causes congenital hypogonadotropic hypogonadism and cerebellar hypoplasia; in Prdm13 mutant mice, there is a significant reduction in hypothalamic Kisspeptin (Kiss1) neurons and PAX2+ cerebellar progenitors, with ectopic expression of glutamatergic marker TLX3, establishing PRDM13 as a regulator of GABAergic fate in the cerebellum and of Kiss1 neuron development in the hypothalamus.\",\n      \"method\": \"Human genetic analysis, mouse Prdm13 mutant allele analysis, immunohistochemistry for Kiss1/PAX2/TLX3, expression studies in mouse and human tissue\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mutant mouse phenotype with specific cellular markers corroborated by human genetic evidence\",\n      \"pmids\": [\"34730112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Biallelic loss-of-function mutations in PRDM13 in humans cause pontocerebellar hypoplasia with dysplasia of the dentate nucleus, inferior olive hypoplasia, and disorganized Purkinje cell layer. In zebrafish, prdm13 loss causes reduction in Purkinje cell numbers and complete absence of inferior olive nuclei. snRNA-seq and ISH show PRDM13 expression in cerebellar ventricular zone GABAergic progenitors (including Purkinje cell precursors).\",\n      \"method\": \"Human genetic analysis (biallelic variants), zebrafish prdm13 loss-of-function, snRNA-seq data mining, in situ hybridization, histopathology\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — zebrafish KO with specific cellular phenotype, human pathology, complementary expression data\",\n      \"pmids\": [\"35390279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Prdm13+ neurons in the dorsomedial hypothalamus are activated during sleep deprivation in young but not old mice; chemogenetic inhibition of DMH Prdm13+ neurons promotes increased sleep attempts during sleep deprivation; DMH-specific Prdm13 KO mice show age-associated sleep fragmentation, increased adiposity, decreased physical activity, and shortened lifespan, with dietary restriction effects on sleep abrogated in KO mice.\",\n      \"method\": \"Chemogenetic (DREADD) inhibition of Prdm13+ neurons, DMH-specific Prdm13 KO, c-Fos immunostaining, EEG/EMG sleep recording, metabolic phenotyping\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — chemogenetics + conditional KO with defined behavioral and physiological phenotypes\",\n      \"pmids\": [\"37045472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Overexpression of PRDM13 in U87 glioma cells decreases proliferation, migration, and invasion; RNA-seq and functional follow-up identified upregulation of DLC1 (deleted in liver cancer 1), a Rho GTPase-activating protein, as a downstream effector of PRDM13-mediated growth suppression.\",\n      \"method\": \"Overexpression in U87 cells, RNA-seq, functional proliferation/migration/invasion assays, western blot validation\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, overexpression with functional assays and RNA-seq, limited mechanistic depth\",\n      \"pmids\": [\"29767251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In mouse embryonic stem cell–derived neuroectoderm organoids, Prdm13 expression inhibits RX+ eye field fate while permitting non-eye field neuroectoderm differentiation; this effect depends on the first and second zinc-finger domains of PRDM13. Mechanistically, Prdm13 activates WNT/β-catenin signaling, downregulating eye field transcription factors; pharmacological WNT inhibition abolishes PRDM13-mediated suppression of eye field fate.\",\n      \"method\": \"mESC-derived organoids, Prdm13 overexpression, domain deletion mutants (zinc-finger 1 and 2), WNT pathway reporter assays, pharmacological WNT inhibition, immunofluorescence\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — domain mutagenesis, pharmacological rescue, organoid system with multiple orthogonal readouts\",\n      \"pmids\": [\"40409260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Elevated PRDM13 in the mouse retina decreases photoreceptor function and survival; transcriptomic profiling revealed that elevated PRDM13 downregulates Prdm1 (a photoreceptor marker) and Nr2e3 (a key photoreceptor specification regulator), as well as NR2E3's direct and indirect targets, and deregulates genes involved in phototransduction and retinal development.\",\n      \"method\": \"Inducible mouse PRDM13 overexpression model, ERG, histology, RNA-seq, qPCR, western blot\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — inducible mouse model with reversal experiment, transcriptomic profiling, and multiple validation methods\",\n      \"pmids\": [\"40824246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In the mouse cerebellum, PRDM13 loss (multiple mutant alleles) causes loss of PAX2+ inhibitory interneurons and Purkinje cells, increased TLX3+ excitatory neurons, increased apoptosis, misplacement of TBR1+ cells, and reduced cerebellar size—phenocopying PTF1A absence and establishing PRDM13 as required downstream of PTF1A for balanced inhibitory/excitatory neuronal specification in the cerebellum.\",\n      \"method\": \"Multiple Prdm13 mutant mouse alleles, immunohistochemistry for PAX2/TLX3/TBR1/Purkinje cell markers, epistasis with Ptf1a\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple alleles phenocopying PTF1A KO, multiple marker readouts, epistatic relationship clearly established\",\n      \"pmids\": [\"40721003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRDM13 binds DNA in a methylation-sensitive manner, with binding to methylated DNA preferred or resulting in discovery of alternative, methylation-dependent binding motifs, as determined by meSMiLE-seq.\",\n      \"method\": \"meSMiLE-seq (microfluidic in vitro DNA binding assay with methylated and unmethylated DNA)\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro biochemical assay, but preprint and single method without cellular validation\",\n      \"pmids\": [\"bio_10.1101_2024.11.11.619598\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"PRDM13 is a transcriptional repressor that acts downstream of the PTF1A-RBPJ complex to suppress glutamatergic/excitatory neuronal fate programs (including TLX1/3 and ventral specification genes) while promoting GABAergic/inhibitory neuronal identity in the dorsal spinal cord, cerebellum, retina, and hypothalamus; it achieves repression by binding regulatory sequences near target genes and interacting with bHLH factors (ASCL1, NEUROG2, and others), requires its zinc-finger domains for DNA binding (including methylation-sensitive binding), activates WNT/β-catenin signaling to suppress eye field fate in retinal progenitors, and when dysregulated (by noncoding variants or gene duplication) causes North Carolina macular dystrophy and related retinal dystrophies, while recessive loss-of-function mutations cause pontocerebellar hypoplasia and congenital hypogonadotropic hypogonadism.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PRDM13 is a transcriptional repressor that functions downstream of PTF1A to suppress excitatory/glutamatergic neuronal fate and promote inhibitory (GABAergic/glycinergic) neuronal identity across multiple regions of the developing nervous system, including the dorsal spinal cord, cerebellum, retina, and hypothalamus. It is recruited to chromatin by neural bHLH transcription factors such as ASCL1 and NEUROG2, where it binds regulatory sequences near target genes (e.g., Tlx1, Tlx3, Olig1/2) to silence excitatory and alternative lineage programs; its zinc-finger domains are required for DNA binding and for suppression of eye field fate through activation of WNT/β-catenin signaling in retinal progenitors [PMID:23639443, PMID:28850031, PMID:40409260]. Biallelic loss-of-function mutations in PRDM13 cause pontocerebellar hypoplasia and congenital hypogonadotropic hypogonadism in humans, while noncoding regulatory variants and gene duplications cause North Carolina macular dystrophy [PMID:35390279, PMID:34730112, PMID:26507665]. In the hypothalamus, PRDM13 marks dorsomedial hypothalamic neurons that regulate sleep homeostasis, and its loss leads to sleep fragmentation, progressive adiposity, and shortened lifespan [PMID:37045472, PMID:25546159].\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"Establishing PRDM13 as the critical downstream effector of PTF1A in dorsal spinal cord that directly represses excitatory fate: prior work identified PTF1A as a master regulator of inhibitory neuron specification, but the mechanism by which it silenced glutamatergic genes was unknown—PRDM13 was shown to directly bind Tlx1/Tlx3 regulatory elements and repress their transcription, while physically interacting with bHLH factor ASCL1 to block ASCL1-mediated Tlx3 activation.\",\n      \"evidence\": \"ChIP, reporter assays, co-immunoprecipitation, gain/loss-of-function epistasis in mouse and Xenopus\",\n      \"pmids\": [\"23639443\", \"24370451\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether PRDM13 possesses intrinsic histone methyltransferase activity was not directly demonstrated\",\n        \"The identity of additional bHLH partners beyond ASCL1 remained unresolved\",\n        \"No genome-wide binding profile was available\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Extending the PTF1A→PRDM13 axis to retinal neuron subtype specification: it was unclear whether PRDM13 had tissue-specific roles beyond spinal cord—knockout and overexpression studies showed PRDM13 specifically promotes GABAergic and glycinergic (but not cholinergic) amacrine cell identity in the retina, acting as a subtype-selective effector downstream of PTF1A.\",\n      \"evidence\": \"Prdm13 KO mice, retroviral overexpression, subtype marker immunohistochemistry in mouse retina\",\n      \"pmids\": [\"25995483\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct transcriptional targets of PRDM13 in retina were not identified\",\n        \"How PRDM13 distinguishes GABAergic/glycinergic from cholinergic amacrine programs was unexplained\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linking PRDM13 regulatory variants to human macular disease: it was unknown which gene was responsible for North Carolina macular dystrophy—noncoding variants upstream of PRDM13 and PRDM13 tandem duplications were identified as causal, establishing that PRDM13 dosage dysregulation disrupts macular development.\",\n      \"evidence\": \"Whole-genome sequencing, co-segregation analysis, RT-PCR in human retinal stem cell-derived cells\",\n      \"pmids\": [\"26507665\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No direct functional assay demonstrated how the noncoding variants alter PRDM13 expression levels\",\n        \"Whether gain versus loss of PRDM13 expression drives macular pathology was not resolved\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Revealing a hypothalamic role for PRDM13 in sleep and metabolic regulation: PRDM13 function had only been studied in neuronal fate specification—discovery of NKX2-1-regulated PRDM13 expression in the dorsomedial hypothalamus and the sleep/adiposity phenotypes upon DMH-specific knockdown established a novel physiological role.\",\n      \"evidence\": \"Laser-capture microarray, promoter reporter, siRNA in primary neurons, DMH-specific lentiviral KD in mice with EEG/EMG and metabolic phenotyping\",\n      \"pmids\": [\"25546159\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The downstream transcriptional targets of PRDM13 in DMH neurons were not identified\",\n        \"Whether PRDM13 acts through the same bHLH-dependent repressor mechanism in hypothalamus was untested\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defining PRDM13 as a genome-wide repressor of alternative neuronal fates recruited by multiple bHLH factors: it was unclear whether PRDM13 only interacted with ASCL1—ChIP-seq and conditional KO transcriptomics showed PRDM13 is recruited by multiple bHLH partners and represses ventral specification genes (Olig1, Olig2, Prdm12) in addition to excitatory markers, broadening its role as a gatekeeper of dorsal identity.\",\n      \"evidence\": \"ChIP-seq, RNA-seq in Prdm13 conditional KO mice, epistasis with multiple bHLH factors\",\n      \"pmids\": [\"28850031\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The biochemical nature of the repressive complex (co-repressors, histone marks deposited) was not characterized\",\n        \"Structural basis for bHLH factor recognition by PRDM13 was unknown\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Refining retinal amacrine subtype roles of PRDM13 and establishing a PTF1A-PRDM13 negative feedback loop: in Xenopus retina, PRDM13 was shown to repress its own upstream activator Ptf1a, creating feedback regulation, while mouse KO confirmed loss of Ebf3+ amacrine subtypes and increased apoptosis.\",\n      \"evidence\": \"Xenopus clonal analysis and morpholino knockdown; mouse Prdm13 KO with fate mapping, TUNEL assay, immunohistochemistry\",\n      \"pmids\": [\"28863786\", \"29258872\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether the negative feedback on Ptf1a is direct or indirect was not resolved\",\n        \"The apoptosis mechanism in amacrine cells lacking PRDM13 was not elucidated\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Establishing PRDM13 as a Mendelian disease gene: recessive PRDM13 mutations in humans were linked to congenital hypogonadotropic hypogonadism and cerebellar hypoplasia, with mouse mutants revealing loss of hypothalamic Kiss1 neurons and cerebellar PAX2+ progenitors with ectopic TLX3 expression—directly connecting the excitatory/inhibitory fate switch to human disease.\",\n      \"evidence\": \"Human genetic analysis, Prdm13 mutant mouse immunohistochemistry for Kiss1/PAX2/TLX3\",\n      \"pmids\": [\"34730112\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The mechanism by which PRDM13 regulates Kiss1 neuron development was not determined\",\n        \"Whether PRDM13 acts cell-autonomously in Kiss1 precursors was not shown\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defining the cerebellar neuropathology of PRDM13 deficiency: biallelic human mutations were shown to cause pontocerebellar hypoplasia with dentate nucleus dysplasia and inferior olive hypoplasia, confirmed by zebrafish prdm13 loss causing Purkinje cell reduction and absent inferior olive, with snRNA-seq localizing PRDM13 to GABAergic ventricular zone progenitors.\",\n      \"evidence\": \"Human neuropathology, zebrafish prdm13 KO, snRNA-seq, in situ hybridization\",\n      \"pmids\": [\"35390279\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The direct transcriptional targets of PRDM13 in the cerebellum were not mapped\",\n        \"Whether pontine defects are secondary to cerebellar or olivary loss was not established\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrating that PRDM13+ DMH neurons are active participants in sleep homeostasis that decline with aging: chemogenetic silencing of these neurons promoted sleep attempts, and DMH-specific Prdm13 KO recapitulated age-related sleep fragmentation and metabolic dysfunction, establishing PRDM13 as functionally required in adult hypothalamic circuits.\",\n      \"evidence\": \"DREADD chemogenetic inhibition, DMH-specific Prdm13 conditional KO, c-Fos, EEG/EMG, metabolic phenotyping\",\n      \"pmids\": [\"37045472\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The molecular targets of PRDM13 in adult DMH neurons are unknown\",\n        \"Whether PRDM13 loss causes neuron loss versus altered function in adult DMH was not distinguished\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Revealing that PRDM13 suppresses eye field fate through WNT/β-catenin activation dependent on its zinc-finger domains, and that elevated retinal PRDM13 is directly toxic to photoreceptors by downregulating Prdm1 and Nr2e3—providing a mechanistic link between PRDM13 dosage and retinal dystrophy.\",\n      \"evidence\": \"mESC-derived organoids with domain deletion mutants and WNT pathway pharmacological rescue; inducible PRDM13 overexpression mouse with ERG, histology, and RNA-seq\",\n      \"pmids\": [\"40409260\", \"40824246\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether WNT activation is a direct or indirect consequence of PRDM13 zinc-finger binding was not determined\",\n        \"The binding sites through which PRDM13 represses Prdm1 and Nr2e3 were not mapped\",\n        \"Whether the photoreceptor toxicity explains human NCMD pathology was not directly tested\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Confirming PRDM13 as essential downstream of PTF1A for balanced inhibitory/excitatory specification in the cerebellum: multiple Prdm13 mutant alleles phenocopied Ptf1a loss with loss of PAX2+ interneurons and Purkinje cells, gain of TLX3+ excitatory neurons, and reduced cerebellar size.\",\n      \"evidence\": \"Multiple Prdm13 mutant mouse alleles, immunohistochemistry for PAX2/TLX3/TBR1/Purkinje cell markers, epistasis with Ptf1a\",\n      \"pmids\": [\"40721003\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether PRDM13 acts in the same progenitor pool as PTF1A or also in postmitotic cells was not resolved\",\n        \"The identity of PRDM13-associated co-repressor complexes in cerebellar progenitors remains unknown\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include the biochemical nature of PRDM13's repressive activity (whether it has intrinsic histone methyltransferase activity, its co-repressor partners, and structural basis for bHLH interaction), the direct genomic targets in hypothalamic and cerebellar tissues, and the precise mechanism by which PRDM13 dosage dysregulation causes North Carolina macular dystrophy.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No reconstituted enzymatic assay has confirmed or excluded intrinsic histone methyltransferase activity\",\n        \"Co-repressor complex composition is entirely uncharacterized\",\n        \"Genome-wide binding data exist only for dorsal spinal cord, not retina, cerebellum, or hypothalamus\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 2, 8, 10, 15, 16]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 8, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 8, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 2, 4, 5, 9, 11, 12, 17]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 8, 15, 16]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [4, 9, 11, 12, 13, 17]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ASCL1\",\n      \"NEUROG2\",\n      \"PTF1A\",\n      \"NKX2-1\",\n      \"DLC1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}